Work Productivity in Hyperventilation Syndrome (WHY)

April 28, 2022 updated by: University Hospital, Lille
Hyperventilation syndrome is associated with impaired quality of life. The aim of the study is to assess the relationship between work productivity, including absenteeism and presenteeism, and the severity of hyperventilation syndrome

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

50

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Lille, France
        • Hôpital Calmette,CHU

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

patients with confirmed hyperventilation syndrome, virgin of any treatment.

Description

Inclusion Criteria:

  • Holders of employment contracts for at least 8 days
  • Diagnosis of hyperventilation syndrome confirmed by:

Compatible symptoms and at least two symptoms reproduced by the hyperventilation challenge test: Nijmegen's score> 23 ; Demonstration of alveolar hyperventilation ( Either on rest blood and / or at rest (PaCO2 at rest <36 mmHg and D (A-a) O2 normal; Either during the HV test (increased recovery time of the basic PETCO2 after voluntary hyperventilation (greater than 5 minutes)

Exclusion Criteria:

  • Existence of another chronic pulmonary disease (asthma, bronchial dilation, COPD, diffuse interstitial pneumonia, neuromuscular pathology ...) or cardiac (rhythm disorder, ischemic heart disease ...) which can participate in dyspnea
  • Psychiatric illness / psychotropic treatment
  • Pregnancy
  • Patient already included in a clinical research protocol involving new therapeutics may not be included in this protocol
  • Specific physiotherapy or previous training

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Hyperventilation syndrome
Other: questionnaire
Work Productivity and Activity Impairment (WPAI) Multidimensional Dyspnea Profile (MDP) Baseline Dyspnea Index (BDI), MOS-SF36, Hospital Anxiety Depression (HAD) Cognitive Failure Questionnaire (CFQ).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Association between the WPAI score and the Nijmegen score
Time Frame: At the time of diagnosis (Baseline)
At the time of diagnosis (Baseline)

Secondary Outcome Measures

Outcome Measure
Time Frame
Association between the WPAI score and dyspnea scales
Time Frame: At the time of diagnosis (Baseline)
At the time of diagnosis (Baseline)
Association between the WPAI score and quality of life scores
Time Frame: At the time of diagnosis (Baseline)
At the time of diagnosis (Baseline)
Association between the WPAI score and PaCO2
Time Frame: At the time of diagnosis (Baseline)
At the time of diagnosis (Baseline)
Association between the WPAI score and the Cognitive Failure Questionnaire score
Time Frame: At the time of diagnosis (Baseline)
At the time of diagnosis (Baseline)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Lille

Investigators

  • Principal Investigator: Cécile Chenivesse, MD, University Hospital, Lille

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

February 6, 2018

Primary Completion (ACTUAL)

February 23, 2021

Study Completion (ACTUAL)

February 23, 2021

Study Registration Dates

First Submitted

September 21, 2017

First Submitted That Met QC Criteria

September 21, 2017

First Posted (ACTUAL)

September 25, 2017

Study Record Updates

Last Update Posted (ACTUAL)

April 29, 2022

Last Update Submitted That Met QC Criteria

April 28, 2022

Last Verified

April 1, 2022

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2016_68
  • 2017-A01542-51 (OTHER: ID-RCB number, ANSM)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hyperventilation Syndrome

Clinical Trials on questionnaire

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United States

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe